Good luck on your journey!
Effectiveness: While individual results may vary, numerous studies suggest that GLP-1 patches can lead to significant weight loss and improved blood sugar levels in many users
Therefore, the present study aimed to investigate whether switching to dulaglutide, a weekly injectable GLP-1 receptor agonist, from insulin improves glycemic control in patients with T2D inadequately controlled with conventional insulin treatment
Optional At-Home Testing: No lab visits or testing are required to begin
As expected, both patient groups had substantially higher ratings of fatigue than controls on Chalder Fatigue Scale (ChFS) (Table 1)
These observations indicate that detoxification capacity is not static, but rather represents a dynamic, inducible adaptive response